Brazil acts to spur domestic production of key medicines

Brazil announced a major initiative Thursday to spur domestic production of medicines and equipment to combat diseases such as Alzheimers.

Alexandre Padilha said the plans call for major government investments in the field, public-private partnerships to produce drugs, and fast-tracking patents and registration of products crucial to .

He estimated that the measures would lead to savings of 354 million reais ($179 million) over five years, because the government currently imports most of the medicines involved and makes them available to the national health system.

"To produce here in Brazil means a saving for the government and the consumer," the Padilha said. "These products can lead to price reductions for the consumer."

He made the announcement at a meeting hosted by the Federation of Industries of the State of Sao Paolo.

He said the would extend seven billion reais ($3.5 billion) in credits to Brazilian firms involved in innovative health projects and pump another 1.3 billion reais ($651 million) into the infrastructure of public laboratories.

He said key regulatory bodies—the National Health Surveillance Agency ANVISA, the National Institute of Intellectual Property (INPI) and the Brazilian Association of Technical Norms (ABNT)—would sign agreements aimed at speeding up the process for obtaining patents and registering products.

add to favorites email to friend print save as pdf

Related Stories

Brazil moves to combat 'crack epidemic'

Dec 07, 2011

The Brazilian government on Wednesday launched a war on what it called a "crack epidemic", including medical treatment for addicts and a crackdown on trafficking, particularly in border areas.

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

20 hours ago

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments